Cantor Fitzgerald Reiterates "Overweight" Rating for SI-BONE (NASDAQ:SIBN)

Cantor Fitzgerald reaffirmed their overweight rating on shares of SI-BONE (NASDAQ:SIBN - Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. Cantor Fitzgerald currently has a $25.00 price objective on the stock. Cantor Fitzgerald also issued estimates for SI-BONE's FY2025 earnings at ($0.64) EPS.

Several other research analysts also recently commented on SIBN. Truist Financial raised their price objective on SI-BONE from $16.00 to $18.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. Needham & Company LLC lifted their price objective on SI-BONE from $20.00 to $24.00 and gave the company a "buy" rating in a report on Tuesday. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, SI-BONE presently has an average rating of "Buy" and an average price target of $24.50.

SI-BONE Trading Up 1.7 %

Shares of NASDAQ SIBN traded up $0.31 during mid-day trading on Tuesday, reaching $18.12. The company had a trading volume of 463,449 shares, compared to its average volume of 360,089. The stock has a market cap of $759.92 million, a price-to-earnings ratio of -19.70 and a beta of 1.17. SI-BONE has a 52 week low of $11.70 and a 52 week high of $19.16. The business's 50-day moving average is $16.11 and its 200-day moving average is $14.79. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22.

Remove Ads

SI-BONE (NASDAQ:SIBN - Get Free Report) last issued its earnings results on Monday, February 24th. The company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.16) by $0.05. The business had revenue of $49.00 million for the quarter, compared to the consensus estimate of $48.87 million. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. Equities analysts expect that SI-BONE will post -0.78 earnings per share for the current year.

Insider Buying and Selling at SI-BONE

In other news, insider Anthony J. Recupero sold 3,670 shares of the business's stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $13.90, for a total value of $51,013.00. Following the completion of the transaction, the insider now directly owns 222,814 shares of the company's stock, valued at approximately $3,097,114.60. The trade was a 1.62 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Anshul Maheshwari sold 5,304 shares of the firm's stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $13.91, for a total value of $73,778.64. Following the sale, the chief financial officer now directly owns 189,319 shares in the company, valued at approximately $2,633,427.29. The trade was a 2.73 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 9,311 shares of company stock valued at $130,356. 3.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Harbor Capital Advisors Inc. boosted its stake in SI-BONE by 222.5% in the third quarter. Harbor Capital Advisors Inc. now owns 620,490 shares of the company's stock valued at $8,674,000 after acquiring an additional 428,110 shares in the last quarter. Champlain Investment Partners LLC lifted its holdings in shares of SI-BONE by 14.7% during the 3rd quarter. Champlain Investment Partners LLC now owns 2,800,073 shares of the company's stock valued at $39,145,000 after purchasing an additional 358,821 shares during the last quarter. Silvercrest Asset Management Group LLC boosted its position in shares of SI-BONE by 21.9% in the 4th quarter. Silvercrest Asset Management Group LLC now owns 1,953,806 shares of the company's stock worth $27,392,000 after purchasing an additional 350,970 shares in the last quarter. American Century Companies Inc. grew its stake in SI-BONE by 11.0% during the 4th quarter. American Century Companies Inc. now owns 2,378,068 shares of the company's stock worth $33,341,000 after buying an additional 236,167 shares during the last quarter. Finally, Impax Asset Management Group plc increased its position in SI-BONE by 41.3% during the 3rd quarter. Impax Asset Management Group plc now owns 758,521 shares of the company's stock valued at $10,604,000 after buying an additional 221,604 shares in the last quarter. Institutional investors own 98.11% of the company's stock.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.